Mepolizumab-based therapy in asthma: An update

Current Opinion in Allergy and Clinical Immunology

Volumn 15, Issue 4, 2015, Pages 392-396

  Walsh, Garry M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

anti IL 5; eosinophilic asthma; exacerbations; mepolizumab

Indexed keywords

BENRALIZUMAB; INTERLEUKIN 5; MEPOLIZUMAB; RESLIZUMAB; IL5 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

APOPTOSIS; ASTHMA; BONE MARROW; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DRUG SAFETY; EOSINOPHIL; EOSINOPHIL COUNT; INFLAMMATION; INNATE IMMUNITY; LUNG FUNCTION; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; HUMAN; IMMUNOLOGY; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; EOSINOPHILS; HUMANS; INTERLEUKIN-5;

EID: 84937809593     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000183     Document Type: Review

References (37)

1. Anandan C, Nurmatov U, van Schayck OC, Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy 2010; 65: 152-167
2. Lockey RF. Asthma phenotypes: an approach to the diagnosis and treatment of asthma. J Allergy Clin Immunol Pract 2014; 2: 682-685
3. Ray A, Oriss TB, Wenzel SE. Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol 2015; 308: L130-L140
4. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005; 25: 552-563
5. Kandeel M, Balaha M, Inagaki N, Kitade Y. Current and future asthma therapies. Drugs Today (Barc) 2013; 49: 325-339
6. Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009; 180: 817-822
7. Berger WE. New approaches to managing asthma: a US perspective. Ther Clin Risk Manag 2008; 4: 363-379
8. Matsumura Y. Inflammatory cellular phenotypes and molecular mechanisms of glucocorticoid resistance in patients with bronchial asthma. Antiinflamm Antiallergy Agents Med Chem 2013; 12: 189-200
9. Shaw DE, Green RH, Bradding P. Asthma exacerbations: prevention is better than cure. Ther Clin Risk Manag 2005; 1: 273-277
10. Holgate ST A look at the pathogenesis of asthma: the need for a change in direction. Discov Med 2010; 9: 439-447
11. Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 2012; 11: 958-972
12. Nair P. What is an eosinophilic phenotype of asthma? J Allergy Clin Immunol 2013; 132: 81-83
13. Walsh GM. Therapeutic potential of targeting interleukin 5 in asthma. Bio-Drugs 2013; 27: 559-5630
14. Blanchard C, Rothenberg ME. Biology of the eosinophil. Adv Immunol 2009; 101: 81-121
15. Nissim Ben Efraim AH, Levi-Schaffer F. Tissue remodeling and angiogenesis in asthma: the role of the eosinophil. Ther Adv Respir Dis 2008; 2: 163-171
16. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 2013; 13: 9-22
17. Lacy P, Rosenberg HF, Walsh GM. Eosinophil overview: structure, biological properties, and key functions. Methods Mol Biol 2014; 1178: 1-12
18. Walsh GM. Advances in the immunobiology of eosinophils and their role in disease. Crit Rev Clin Lab Sci 1999; 36: 453-496
19. Robinson DS. Mepolizumab for severe eosinophilic asthma. Expert Rev Respir Med 2013; 7: 13-17
20. Walsh GM. Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma. Biologics 2013; 7: 7-11
21. Corren J. Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discovery Med 2012; 13: 305-312
22. Ghazi A, Trikha A, Calhoun WJ. Benralizumab-A humanized mAb to IL-5Ra with enhanced antibody-dependent cell-mediated cytotoxicity-A novel approach for the treatment of asthma. Expert Opin Biol Ther 2012; 12: 113-118
23. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984
24. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisonedependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993
25. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659
26. Liu Y, Zhang S, Li DW, Jiang SJ. Efficacy of antiinterleukin-5 therapy with mepolizumab in patients with asthma: a meta-Analysis of randomized placebocontrolled trials. PLoS One 2013; 8: e59872
27. Nair P. Antiinterleukin-5 monoclonal antibody to treat severe eosinophilic asthma. N Engl J Med 2014; 371: 1249-1251
28. Bel EH, Wenzel SE, Thompson PJ, et al. Pavord ID; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371: 1189-1197
29. Ortega HG, Liu MC, Pavord ID, et al., MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: 1198-1207
30. Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an antiinterleukin 5 receptor a monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014; 2: 879-890
31. Nowak RM, Parker JM, Silverman RA, et al A randomized trial of benralizumab, an antiinterleukin 5 receptor a monoclonal antibody, after acute asthma. Am J Emerg Med 2015; 33: 14-20
32. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3: 355-366
33. Hilvering B, Xue L, Pavord ID. Evidence for the efficacy and safety of antiinterleukin-5 treatment in the management of refractory eosinophilic asthma. Ther Adv Respir Dis 2015; pii: 1753465815581279. [Epub ahead of print] Excellent up-To-date review on the rational of targeting IL-5 and the efficacy and safety of anti-IL-5 biologics in refractory eosinophilic asthma
34. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27: 483-494
35. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455-2466
36. Holgate ST. Innate and adaptive immune responses in asthma. Nat Med 2012; 18: 673-683
37. Aryan Z, Holgate ST, Radzioch D, Rezaei N A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma. Int Arch Allergy Immunol 2014; 164: 46-63